Successful long-term management of primary gout in the presence of normal renal function may be achieved in most instances by agents which diminish tubular reabsorption of urates, thus permitting increased urinary urate excretion. In recent years the two most widely used uricosuric agents have been probenecid and sulphinpyrazone. The easiest longterm control of gout with the fewest untoward sideeffects has been achieved with sulphinpyrazone (Gutman and Yui, 1957a; Kersley, Cook, and Tovey, 1958; Ogryzlo and Harrison, 1957; Kuzell, Glover, Gibbs, and Blau, 1964) .
In spite of the relative ease in controlling gout with sulphinpyrazone, any large group of gouty patients will include some in whom the use of uricosuric agents may be impossible or inadvisable because of impairment of renal function or drug intolerance. Some patients, for reasons not yet understood, form tophi much more readily than others, and quite large dosages of uricosuric agents may arrest the formation of tophi without rapidly diminishing those already present. Some form urate stones in the urinary tract so readily that increasing the urinary output of urates may be hazardous. Finally, in secondary gout attended by excessive uric acid formation, the employment of uricosuric agents may be inadvisable because any increase in the already high excretion rate may lead to obstruction of the lower urinary tract by concretions of uric acid.
A novel approach in the control of gout is offered by allopurinol, 4-hydroxypyrazolo (3, 4-d) pyrimidine (4-HPP), an inhibitor of xanthine oxidase which prevents conversion of hypoxanthine to xanthine and of xanthine to uric acid (Rundles, Wyngaarden, Hitchings, Elion, and Silberman, 1963; Yu and Gutman, 1964; Rundles, Metz, and Silberman, 1966b) . Uric acid available for excretion is diminished, and the relatively more soluble xanthines are readily excreted, thus permitting the use of *Address all communications to William C. Kuzell, M.D., 450 Sutter Street, San Francisco, California, 94108, U.S.A. allopurinol in the presence of impaired renal function. It then appeared attractive to explore the possibility of hastening the mobilization of stored urates and regression of tophi by concurrently inhibiting uric acid formation while enhancing its urinary excretion. Several preliminary clinical studies have, in fact, indicated that the combined use of allopurinol and uricosuric agents promotes more rapid disappearance of tophi (Smyth, 1965; Houpt, 1965; Kuzell, Glover, Seebach, Gibbs, and Jackman, 1965; Rundles and others, 1966b; Rundles. Elion. and Hitchings, 1966a) .
Material and Methods The 48 patients selected for this clinical evaluation had all, save two (Table II, Cases 5 and 19) , been under treatment for variable periods from 1 month to 8 years. They were all seen by more than one physician.
Serum uric acid (SUA) and urinary uric acid (UUA) determinations were done by the enzymatic method (Feichtmeir and Wrenn, 1955) . Urinary xanthine determinations were done by a modification of the method of Kalckar (1947) in which diluted urine was incubated in 0-1 M. tris buffer, pH 8-0, in the presence of milk xanthine oxidase* and the resulting excess of uric acid liberated was determined by the difference between the uric acid content of the treated sample and that of an untreated control. Although the substance measured is uric acid, the oxypurines are reported by calculation as mg. xanthine, with no attempt to identify the actual percentage derived from hypoxanthine.
Many of the patients were subjected to extensive laboratory testing before and during the clinical trial. The tests included complete blood count, erythrocyte sedimentation rate, urine analysis, serum uric acid, urinary uric acid, urinary oxypurines, serum glutamic oxaloacetic transaminase (SGOT), cephalin cholesterol flocculation, thymol turbidity, alkaline phosphatase, creatinine, bilirubin, cholesterol, alpha and beta cholesterol, serum protein electrophoresis, and blood urea nitrogen (BUN).
Observations were made at various intervals depending upon the seriousness of the clinical problem considered. 
Results
Combined Treatment Allopurinol and sulphinpyrazone were given together to twenty male patients, who were divided into those with and those without visible tophi (Table I) (Table II) .
(A) Impaired Renal Function (4).-Cases 1 and 2 had previously been unable to take uricosuric agents because of severely impaired renal function; each had multiple tophi ranging from 2 mm. to several centimetres in diameter, which tophi had been steadily increasing in size.
Case 1 (aged 85) was able to tolerate from 400 to 600 mg./day allopurinol for 270 days, during which the SUA level fell from 11 -35 to 5 40 mg./100 ml., the tophi became smaller and softer, and his range of general physical activity increased. Unfortunately, he died from cerebral haemorrhage at a time when the gout was under control.
Case 2 continued to take 300 to 500 mg./day allopurinol for 486 days; the SUA has fallen from 8-98 to 5-74 mg./100 ml., the tophi have not increased in number, and some of them have become softer and smaller. She has experienced less pain and the renal function has remained unchanged.
Cases 3 and 4 had previously passed urate stones. In Case 3, sulphinpyrazone had previously prevented attacks of acute gout, but stones continued to form, and Case 19, a cardiac patient with osteoporosis and gout, not previously treated, experienced marked reduction in SUA and was able to tolerate thiazide diuretics when taking only 100 mg. day allopurinol.
Case 28 had suffered from leg muscle pains when taking oxyphenbutazone, but on 100 mg. day allopurinol the pains subsided.
Cases 22, 23, and 24 had had no gouty attackls when taking sulphinpyrazone previously but since they were also taking thiazide diuretics the SUA remained high. When they took allopurinol the gout remained under control and the SUA became normal.
Cases 20, 21, and 27, previously controlled on sulphinpyrazone, remained symptom-free on allopurinol.
Case 25, who had difficulty swallowing pills, objected to the "bitter taste" of sulphinpyrazone but was able to chew allopurinol tablets without complaint.
Toxic Manifestations
In only two instances was allopurinol discontinued because of undesirable side-effects.
A 62-year-old man (Table I , Case 3) with gout, chronic pyelonephritis, and chronic lymphatic leukaemia, while taking allopurinol 200 mg. and sulphinpyrazone 300 mg./ day for 120 days, experienced headache, nausea, and vertigo. These symptoms were related to taking allopurinol, and he has been able to take sulphinpyrazone subsequently without difficulty.
A 69-year-old male (Table II , Case 12) with severe gout, who had previously experienced a transient leucopenia on sulphinpyrazone, was forced to discontinue medication after 42 days on 200 mg./day allopurinol because of nausea, diarrhoea, and a severe furunculosis of the nose.
An 85-year-old male (Table II , Case 1), with severe tophaceous gout and impaired renal function, was able to take 400 to 600 mg./day allopurinol for 270 days; the SUA fell from 11 5 to 5 4 mg./100 ml. with marked softening and diminution in size of multiple tophi. This patient died from a cerebral haemorrhage after a 2-day illness. The day before he died the leucocyte count fell to 2,800 with 28 per cent. neutrophils, I metamelocyte, 10 lymphocytes, and 5 per cent. monocytes. Occasional Dohle bodies were seen in the leucocytes. The serum creatinine varied between 2 5 and 4-5 mg./100 ml. before and during treatment with allopurinol. The diminution in leucocytes in this aged man could have been due to overwhelming infection. Permission for autopsy was not granted. We cannot with certainty attribute the blood changes to allopurinol.
Six other patients experienced undesirable sideeffects:
(1) A man aged 61 (Case 18, Table II ) with chronic myelogenous leukaemia, probable duodenal ulcer, and secondary gout, had nausea directly related to allopurinol. This was prevented by placing crushed tablets in gelatin capsules. While on allopurinol he experienced a severe gastro-intestinal haemorrhage and had to be given a blood transfusion. Subsequently he was treated with p32 and has successfully resumed treatment with allopurinol in capsules together with appropriate treatment for duodenal ulcer.
(2) A man aged 54 (Case 13, Table II ) with rheumatoid arthritis and probable gout, complained that his smoking tobacco had an "acid taste" when he was taking allopurinol, but he has successfully continued treatment.
(3) A woman aged 73 (Case 2, Table II) , with severe tophaceous gout, one kidney, impaired renal function, psoriasis, and multiple drug sensitivities, developed a transitory fine maculo-papular rash after beginning treatment with allopurinol. She was subsequently able to continue treatment without difficulty.
(4) A man aged 67 (Case 23, Table II) , with probable gout, atrial fibrillation, mitral stenosis (inoperable), and cardiac insufficiency, experienced diarrhoea for several weeks, but successfully continued treatment with allopurinol.
(5) A man aged 51 (Case 8, Table I) , with severe gout, experienced moderately severe diarrhoea, but as treatment was continued the diarrhoea lessened.
(6) A man aged 69 (Case 13, Table I ), with severe tophaceous gout and old ankylosing spondylitis, experienced severe nausea whenever the daily dosage of allopurinol exceeded 400 mg.
Previous investigators have reported that allopurinol tended to bring on acute gouty arthritis with increased frequency during the first few weeks of treatment, but this was not observed in our study, doubtless because of prolonged previous medication with uricosuric agents and perhaps also because of our practice of employing smaller average daily doses of allopurinol.
Laboratory Results
During this study numerous laboratory examinations were made of the blood and urine. No abnormality was noted other than the single instance of leucopenia (Case 1, Table II) described above. No hepatic abnormality was seen. Oxypurines were recovered from the urine uniformly in patients receiving allopurinol alone or in combination with sulphinpyrazone.
Discussion
The use of allopurinol, a structural analogue of hypoxanthine, as an inhibitor of xanthine oxidase activity in gout has extended the scope of treatment to include several groups of patients previously beyond the reach of therapy.
Since impairment of renal function has been a contraindication to the use of uricosuric agents, the availability of allopurinol for such patients has been a great advance in the therapy of gout. Although they are relatively few in relation to the total gouty population, their previous inexorable progression has been witnessed with helplessness and chagrin by the physician. Our favorable results in patients with impaired renal function (Cases 1 and 2, Table  II ) have confirmed the observations of Rundles and others (1963), and Yu and Gutman (1964) .
Since allopurinol diminishes uric acid formation, the concentration of uric acid in the renal tubular filtrate falls to levels not readily conducive to stone formation. This observation has led to the use of allopurinol in those gouty patients who form urate stones quickly and frequently particularly when treated with uricosuric agents. Our experience in Cases 3, 6, 7, 15, 16 (Table I) and 3, 4 (Table II) emphasizes the importance of using allopurinol only one of the seven passed a single stone during the period of this study.
While it is generally accepted that most gouty patients can be controlled effectively with uricosuric agents (particularly sulphinpyrazone), the addition of allopurinol to the treatment of patients with massive tophi has hastened their softening and resolution (Table I) . Combined therapy diminishes the increment in uric acid production while augmenting output of UUA. This combined therapeutic approach may be expected to "pull out" stored uric acid, making it available for excretion thus accelerating the rate of resolution of tophi. This idea was substantiated by the rapid softening and shrinking of tophi in eleven of twelve patients with tophi who received the combined treatment; with sulphinpyrazone alone, the tophi decreased only slowly or not at all.
There are other special problems in cases of gout in which allopurinol may be used alone:
(i) Active peptic ulcer aggravated by uricosuric agents.
(ii) Toxic side-effects of uricosuric agents.
(iii) Hyperuricaemia with rheumatoid arthritis, particularly when thiazide diuretics are concurrently employed.
(iv) Psoriasis, in which the formation of uric acid is augmented in proportion to the area of skin involvement.
(v) Secondary gout, in which the formation of uric acid is often massive secondary to disorders of haematopoiesis or to the use of cytotoxic agents.
Since thiazide diuretics reduce the excretion of uric acid, when their use is essential in the gouty patient, our studies have demonstrated that small doses of allopurinol-usually 100 to 200 mg./day-suffice to reduce SUA levels to normal. This is an area of therapeutic usefulness of allopurinol which deserves further study because of the widespread use of these diuretics.
The toxicity of allopurinol in our hands has not been alarming; only two of 48 patients were obliged to discontinue its use, and six other patients, in whom toxic manifestations included nausea, diarrhoea, and rash, have been able to continue treatment with subsidence of symptoms.
In one instance of leucopenia, as part of the terminal episode in an 85-year-old man with cerebral haemorrhage, the diminution in leucocytes could not with certainty be ascribed to allopurinol. Our patients have been able to achieve clinical control of gout in most instances using daily doses of 200 to 400 mg. which are lower than those often employed. Admittedly, the treatment with allopurinol could have been more vigorous; but since the patients were doing well clinically this did not appear to be necessary, and we feel that the use of low dosage schedules accounts for our relatively low incidence of diarrhoea and of the augmented attack rate of acute gout previously reported (Yu and Gutman, 1964; Rundles and others, 1966b (usually 200 to 400 mg./day) our patients did not experience the high incidence of diarrhoea and flare-up of acute gout previously reported.
